Cargando…
The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer
Expression of hypoxia-inducible factor (HIF)1α increases the risk of castrate-resistant prostate cancer (CRPC) and metastases in patients on androgen deprivation therapy (ADT) for prostate cancer (PC). We aimed to investigate the effects of nonspecific HIF1α inhibitors (Digoxin, metformin, and angio...
Autores principales: | Ranasinghe, Weranja K B, Sengupta, Shomik, Williams, Scott, Chang, Mike, Shulkes, Arthur, Bolton, Damien M, Baldwin, Graham, Patel, Oneel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987074/ https://www.ncbi.nlm.nih.gov/pubmed/24464861 http://dx.doi.org/10.1002/cam4.189 |
Ejemplares similares
-
The Role of Hypoxia-Inducible Factor 1α in Determining the Properties of Castrate-Resistant Prostate Cancers
por: Ranasinghe, Weranja K. B., et al.
Publicado: (2013) -
Zinc ion dyshomeostasis increases resistance of prostate cancer cells to oxidative stress via upregulation of HIF1α
por: Wetherell, David, et al.
Publicado: (2018) -
Corrigendum to “Targeting HIF-1α to Prevent Renal Ischemia-Reperfusion Injury: Does It Work?”
por: Sethi, Kapil, et al.
Publicado: (2019) -
Zinc Preconditioning Provides Cytoprotection following Iodinated Contrast Media Exposure in In Vitro Models
por: Perera, Marlon, et al.
Publicado: (2021) -
Survival outcomes of younger men (< 55 years) undergoing radical prostatectomy
por: Tan, Lynn, et al.
Publicado: (2018)